GSK PLC Sponsored ADR $GSK Stock: TD Waterhouse Canada Inc. Increases Holdings

TD Waterhouse Canada Inc. boosted its stake in GSK PLC Sponsored ADR (NYSE:GSK) by 51.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,653 shares of the pharmaceutical company’s stock after purchasing an additional 21,400 shares during the period. TD Waterhouse Canada Inc.’s holdings in GSK were worth $2,957,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Security National Bank of SO Dak acquired a new position in shares of GSK during the second quarter worth about $38,000. Trust Co. of Vermont purchased a new stake in shares of GSK in the second quarter worth about $54,000. Philadelphia Investment Partners LLC purchased a new stake in shares of GSK in the second quarter worth about $70,000. Ancora Advisors LLC purchased a new stake in shares of GSK in the second quarter worth about $71,000. Finally, Bogart Wealth LLC grew its stake in shares of GSK by 15.3% in the first quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock valued at $83,000 after buying an additional 200 shares in the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GSK has been the topic of several analyst reports. Jefferies Financial Group reiterated a “buy” rating on shares of GSK in a report on Monday, September 28th. Royal Bank Of Canada started coverage on GSK in a research report on Tuesday, September 8th. They set a “sector perform” rating on the stock. Deutsche Bank Aktiengesellschaft restated a “neutral” rating on shares of GSK in a report on Tuesday, September 29th. Sanford C. Bernstein reaffirmed a “buy” rating on shares of GSK in a research report on Sunday, August 2nd. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating on shares of GSK in a research report on Monday, June 29th. Four research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, GSK has a consensus rating of “Hold” and an average price target of $55.33.

GSK Stock Performance

Shares of GSK stock opened at $50.60 on Wednesday. GSK PLC Sponsored ADR has a 12 month low of $42.85 and a 12 month high of $61.69. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52. The firm has a market capitalization of $102.34 billion, a P/E ratio of 15.82, a P/E/G ratio of 2.23 and a beta of 0.33. The company’s fifty day moving average price is $49.55 and its two-hundred day moving average price is $51.54.

GSK (NYSE:GSK) last posted its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.09. The company had revenue of $11.14 billion during the quarter, compared to analysts’ expectations of $11.02 billion. GSK had a net margin of 14.56% and a return on equity of 43.23%. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.47 EPS. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, research analysts anticipate that GSK PLC Sponsored ADR will post 4.78 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 8th. Stockholders of record on Friday, August 14th were given a dividend of $0.4515 per share. The ex-dividend date of this dividend was Friday, August 14th. This is a positive change from GSK’s previous quarterly dividend of $0.44. This represents a $1.81 dividend on an annualized basis and a dividend yield of 3.6%. GSK’s dividend payout ratio is presently 55.31%.

Trending Headlines about GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: The FDA granted accelerated approval to GSK’s Jemperli (dostarlimab) for adults with locally advanced rectal cancer characterized by MSI-H or dMMR biomarkers. The approval expands Jemperli’s commercial opportunity and strengthens GSK’s position in biomarker-driven cancer treatment. GSK Immunotherapy Gets Accelerated FDA Approval for Treating Rectal Cancer
• Positive Sentiment: U.S. regulators approved GSK’s hepatitis B drug, offering eligible patients the possibility of stopping long-term treatment. The product could address a significant unmet need and create a new growth driver if adoption is strong. US FDA approves GSK’s hepatitis B drug
• Positive Sentiment: GSK reported encouraging early data for experimental lung cancer therapy risvutatug rezetecan. The drug produced a 61% confirmed response rate at the 8 mg/kg dose in relapsed extensive-stage small-cell lung cancer, compared with 32% at the lower dose. The results improve the drug’s potential value, although the trial remains early-stage. GSK lung cancer drug shows 61% response rate in early global trial
• Positive Sentiment: Jefferies maintained a “buy” rating and set a 2,500-pence price target, citing the lung cancer data and potential upside for GSK. The endorsement reinforces investor confidence in the company’s pipeline. Jefferies backs GSK with 2,500p target
• Neutral Sentiment: Analysts have highlighted GSK’s newer medicines, expanded indications and pipeline as potential drivers of long-term sales growth, but much of that outlook depends on successful late-stage development, regulatory approvals and commercial execution.

GSK Company Profile

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.